LIGAND PHARMACEUTICALS INC. overview

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will host an Analyst Day on Tuesday, March 12, 2019 from 10:00 a.m. to 12:00 p.m. Eastern time (7:00 a.m. to 9:00 a.m. Pacific time) in New York City. Company presenters will include John Higgins, CEO, Matt Foehr, COO, and Matt Korenberg, CFO. In addition, Mike Wood, Ph.D., Vernalis, a Ligand Company, Research Director and Cambridge Site Head will present. Ligand has over 110 corporate partners advancing more than 200 Shots-on-Goal. For this...

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and 12 months ended December 31, 2018, and provided an operating forecast and program updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions. “The fourth quarter of 2018 capped off a year of superior financial and operational performance by Ligand and our partners. Promacta showed impressive revenue growth,...

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide OmniAb partnership with Genagon Therapeutics AB, an immuno-oncology focused biotech located in Sweden. Under the terms of the partnership, Genagon gains access to the full OmniAb platform including OmniRat ® , OmniMouse ® , OmniFlic ® and OmniChicken ™ in their drug discovery efforts. Ligand received an upfront payment and is eligible to receive development milestone payments and tiered royalties...

Wolf Popper LLP Announces Investigation on Behalf of Investors in Ligand Pharmaceuticals Incorporated PR Newswire NEW YORK, Jan. 16, 2019 NEW YORK , Jan. 16, 2019 /PRNewswire/ -- Wolf Popper LLP is investigating potential securities fraud claims on behalf of investors in Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) during the period May 9, 2017 through January 14, 2019 , who have incurred losses on their investments in Ligand's securities. Ligand investors should contact Robert Finkel at...

Rev. Fr. Emmanuel Lemelson Renews Call for Investigation in Alleged Accounting and Securities Fraud, SEC Failures, at Ligand Pharmaceuticals Failure to prosecute Alleged Multi-Year Accounting and Securities Fraud at Ligand Pharmaceuticals (NASDAQ: LGND) Diminishes SEC Credibility, Warrants Investigation PR Newswire MARLBOROUGH, Mass., Jan. 16, 2019 MARLBOROUGH, Mass. , Jan. 16, 2019 /PRNewswire/ -- Rev. Fr. Emmanuel Lemelson , the CIO of Lemelson Capital Management, LLC, a U.S.-based global...

Former California Deputy Attorney General and Special Prosecutor with Johnson Fistel Launches Investigation into Ligand Pharmaceuticals; Investors Suffering Losses Encouraged to Contact Firm PR Newswire SAN DIEGO, Jan. 16, 2019 SAN DIEGO , Jan. 16, 2019 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP with the assistance of former California Deputy Attorney General and Special Prosecutor, Tiffany Johnson, Esq. , is investigating potential claims against Ligand Pharmaceuticals...

Wayne, PA, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a rare disease biopharmaceutical company focused on developing and commercializing pathogenetically targeted therapies for debilitating genetic diseases with no approved treatments, today announced that the company has entered into a development funding and royalties agreement with Ligand Pharmaceuticals, Inc. (NASDAQ: LGND) to advance Palvella’s lead product candidate PTX-022 (QTORIN™ rapamycin formulation) for the...